Format

Send to

Choose Destination
Dermatol Clin. 2019 Jan;37(1):29-36. doi: 10.1016/j.det.2018.07.004. Epub 2018 Nov 1.

Biologics and Psoriasis: The Beat Goes On.

Author information

1
Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, 5th Floor, PO Box 1048, New York, NY 10029, USA.
2
Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, 5th Floor, PO Box 1048, New York, NY 10029, USA. Electronic address: lebwohl@aol.com.

Abstract

Psoriasis is a chronic, immune-mediated, inflammatory skin disease that requires long-term therapy for disease control. This article reviews data presented in clinical trials to evaluate and compare various characteristics of biologics that are currently approved for the treatment of psoriasis. Attributes of biological agents that are examined in this article include efficacy, long-term maintenance, overall safety, median time to onset of efficacy, adjustment for body weight, frequency of injections, indication for psoriatic arthritis, and safety in pregnancy. Here, we evaluate what the ideal choice of biological therapy may be for psoriasis patients with specific needs.

KEYWORDS:

Biologics; Efficacy; Psoriasis; Psoriatic arthritis; Safety; Th17/IL-23 axis

PMID:
30466686
DOI:
10.1016/j.det.2018.07.004

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center